Anti-Met (c-Met) antibody (ab10728)
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: None
- Concentration information loading...
- PurityImmunogen affinity purified
- Primary antibody notes The detection limit in immunoblotting for recombinant human HGF R is approximately 5 ng/lane under non-reducing and reducing conditions. Both the alpha and beta chains of HGF R are detected by this antibody under reducing conditions. The detection limit in ELISA for recombinant human HGF R is approximately 0.16 ng/well.
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab10728 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||ICC/IF: Use at an assay dependent concentration.|
|Neutralising||Neut: Use a concentration of 0.5 - 2 µg/ml. ab10728 has the ability to neutralize receptor-ligand interaction. Approximately 0.5-2 mg/mL of the antibody will block 50% of the binding of recombinant human HGF (5 ng/mL) to immobilized recombinant human HGF R/Fc Chimera (100 mL of a 1 mg/mL solution coated in each well) in an ELISA. 10 mg/mL of the antibody will block 90% of binding.|
|ELISA||ELISA: Use a concentration of 0.5 - 1 µg/ml.|
|WB||WB: Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 129 kDa.|
- FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
- Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
- Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
- DomainThe kinase domain is involved in SPSB1 binding.
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
- Cellular localizationMembrane.
- AUTS9 antibodyc met antibodyc met antibody
- cmet antibodycmet antibodyD249 antibodyHepatocyte growth factor receptor antibodyHepatocyte growth factor receptor Precursor antibodyHepatocyte growth factor receptor Precursor antibodyHGF antibodyHGF receptor antibodyHGF receptor antibodyHGF SF receptor antibodyHGF SF receptor antibodyHGF/SF receptor antibodyHGFR antibodyMET antibodyMet proto oncogene tyrosine kinase antibodyMet proto oncogene tyrosine kinase antibodyMet proto-oncogene (hepatocyte growth factor receptor) antibodyMet proto-oncogene antibodyMet protooncogene antibodyMET_HUMAN antibodyOncogene MET antibodyOncogene MET antibodyPar4 antibodyProto-oncogene c-Met antibodyRCCP2 antibodyRenal cell carcinoma papillary 2 gene antibodyRenal cell carcinoma papillary 2 gene antibodyScatter factor receptor antibodySF receptor antibodyTyrosine-protein kinase Met antibody
Anti-Met (c-Met) antibody images
ab10728 staining mouse muscle cells by ICC/IF. Cells were PFA fixed and permeabilized in 0.5% Triton prior to blocking with 1% serum for 30 minutes at 25°C. The primary antibody was diluted 1/50 and incubated with the sample for 1 hour at 25°C. An Alexa Fluor® 488 conjugated chicken anti-goat antibody was used as the secondary.
References for Anti-Met (c-Met) antibody (ab10728)
This product has been referenced in:
- Yan K et al. MicroRNA-34a Inhibits the Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo. PLoS One 7:e33778 (2012). WB ; Mouse . Read more (PubMed: 22457788) »